Psychedelic Brief launched in May, so most of this half-year occurred before this newsletter existed. That's a gap worth closing, because the first half of 2026 was the most consequential six months this field has had in Europe, and the weekly issues will keep referring back to it. So here is the half-year, in one piece: what happened, what it means, and what I'd watch in H2. Every claim is linked at the bottom.

The short version. Three forces defined H1 2026. First, the United States went from cautious to accelerationist in a single quarter, and the consequences of that do not stay in the United States. Second, Europe's quiet "access first, approval later" experiment grew from anecdote into law and data. Third, the European pipeline, the actual drugs being developed by European-rooted companies, had its best half-year on record, even as the capital and regulatory machinery around it stayed stubbornly American.

On 17 February, Compass Pathways announced that COMP006, the second of its two Phase 3 trials of COMP360 psilocybin in treatment-resistant depression, met its primary endpoint: a −3.8 point difference on the MADRS between the 25 mg and 1 mg arms at Week 6, p<0.001. With COMP005 having already read out positive in June 2025, synthetic psilocybin now has two positive pivotal trials. That sentence could not have been written in any previous half-year of this field's existence.

What followed was faster than the data. The FDA granted Compass a rolling NDA submission, and sections are already filed. Then, on 18 April, the White House signed an executive order - "Accelerating Medical Treatments for Serious Mental Illness" - directing the FDA to issue Commissioner's National Priority Vouchers to breakthrough-designated psychedelics, instructing the DEA to prepare rapid rescheduling of anything that clears Phase 3, and putting $50 million behind federal-state research matching. Six days later, the FDA issued vouchers to three programs, Compass's COMP360 among them. The voucher is intended to compress FDA review of a completed application from the usual multi-month cycle toward a one-to-two-month window. Compass still guides to early Q3 for the 26-week COMP006 data and Q4 for completing the NDA.

Hold the caveats firmly. An executive order approves nothing; the evidentiary bar at FDA is unchanged, and the −3.8 point effect size will be argued over by payers and psychiatrists for years; it is statistically unambiguous and clinically modest. The 26-week durability data, due within weeks, is the real remaining risk. I will report it when it exists, not before.

But here is the European read, and it is uncomfortable. If COMP360 is approved in the US on anything like this timeline, conceivably within twelve months, Europe will face an approved psilocybin therapy abroad, fragmentary access at home, and no EMA filing decision of its own to point to. Pricing benchmarks, treatment-delivery models, and reimbursement arguments will be set in the American market and imported, not negotiated here. The bellwether is American. The consequences are not. That asymmetry is the single most important strategic fact in European psychedelic medicine right now.

While Washington signed orders, Europe did something slower and arguably more interesting: it kept building patient access from the bottom up, country by country, ahead of any approval.

On 1 January, the Czech Republic became the first EU member state with a full legal framework for prescribing psilocybin. Under a 2025 criminal-code amendment and a December government decree, certified psychiatrists can administer synthetic psilocybin to adults with treatment-resistant depression and in palliative care, under strict dosing caps and mandatory psychotherapy. Capacity is small and insurance coverage is still being negotiated, so patient numbers in year one will be modest. The precedent is not modest. An EU member state now has a working legal template that every other health ministry in the bloc can copy, criticize, or be lobbied with.

Germany's compassionate-use programme, approved by BfArM in July 2025 for two sites, CIMH Mannheim and OVID Clinic Berlin, using Filament Health's botanical psilocybin PEX010 - spent H1 as the EU's only operating expanded-access route, with demand acknowledged to far exceed its roughly fifty-patients-a-year capacity. And in June, Switzerland's older exceptional-licence route produced what these programmes have always lacked: peer-reviewed real-world data. The Lancet Regional Health, Europe published outcomes from 19 patients treated with psilocybin in Zurich, with clinician-rated depression scores falling from roughly 31 to 20 within six weeks of final dosing. Nineteen patients, no control arm, expectation effects unmeasured — a signal, not proof. But it is the first real read on what Europe's access-first model actually produces, and it is broadly consistent with the trials.

France joined the pattern from two directions: on 9 March, the ANSM established a compassionate prescription framework for generic intravenous racemic ketamine in adults in severe suicidal crisis, a narrow, hospital-based route, and a markedly cheaper one than branded esketamine, and GHU Paris, the largest mental-health hospital system in the capital, took on a regulated psilocybin trial supplied by Filament. Notice the supply layer: the same GMP producer now sits beneath the German programme, UK trials, and France's newest site. Access in Europe is fragmented; the infrastructure underneath it is consolidating.

Two European-rooted companies now sit near the front of the global race, and both spent H1 converting promise into process.

AtaiBeckley, the company formed when Berlin-born atai completed its $390 million acquisition of Oxford's Beckley Psytech in November, cleared its End-of-Phase 2 meeting with the FDA in March and confirmed its Phase 3 pivotal programme for BPL-003, its mebufotenin (5-MeO-DMT) nasal spray for treatment-resistant depression, on track to start in Q2 2026, with topline from two parallel pivotal studies guided for early 2029 and cash to match. Its Phase 2a data was published in the Journal of Psychopharmacology in March; EMP-01, its oral R-MDMA for social anxiety, posted positive Phase 2a results; VLS-01, the DMT buccal film, reads out in Q4. The company also entered the S&P Biotechnology Select Industry Index in Q1 - a small line in a press release that matters more than it looks, because index inclusion pulls in passive institutional money that does not otherwise touch psychedelics.

Dublin's GH Research had the half-year it needed. Its Phase 2b results for GH001 - inhaled mebufotenin, the same molecule as BPL-003 in a different route - were published in JAMA Psychiatry on 25 March: a −15.5 point placebo-adjusted MADRS reduction at Day 8, with high remission rates that a companion analysis found held regardless of how many prior treatments patients had failed. It completed the enrollment that locked its Phase 3 doses, finished its US IND-opening study, raised fresh capital in an April offering, and reported $267 million on hand. The 5-MeO-DMT lane is now a two-horse European race, and both horses are heading into pivotal trials at the same time. Whoever reaches the market first sets the template for the class.

And the EMA, so often the silent character in these reviews, finally appeared on stage: on 19 March, bretisilocin, a short-acting psychedelic originally developed by Gilgamesh Pharmaceuticals and acquired by AbbVie in 2025, became the first psychedelic compound accepted into the agency's PRIME priority-medicines scheme, for major depressive disorder. PRIME is not approval and not even a filing; it is an enhanced regulatory dialogue. But it is the first time the EU's central regulator has formally put a psychedelic on its priority track, and the buyer is the detail to sit with: large pharma is now carrying a psychedelic through the EMA's front door.

The unglamorous layer advanced too. PAREA convened the first European Forum of National Psychedelic Societies in Brussels on 7 May, pulling organisations from 25 countries into one room, the kind of coordination infrastructure that precedes policy, not follows it. A day earlier, the European Parliament hosted a session on psychedelic therapies for war-related trauma in Ukraine, the first time that frame has had a Brussels platform. And the EU's broader pharmaceutical legislation revision, with its regulatory-sandbox concept, moved through 2026 as the sleeper file that could eventually give experimental access models like Germany's and Czechia's an EU-level home.

The 26-week COMP006 durability data, expected early Q3, is the last major evidentiary risk before Compass's Q4 NDA completion. First patients dosed in AtaiBeckley's ReConnection Phase 3 programme. VLS-01 topline in Q4. Whether GH Research formally starts its pivotal programme and where its European sites will be. Czech implementation numbers are the first real test of whether a legal framework translates into treated patients. German compassionate-use capacity, and whether a third site is added. And whether Bretisilocin's PRIME entry stays a one-off or becomes a queue.

Nothing is approved in Europe. The access programmes treat dozens of patients, not thousands. Most of the celebrated data is open-label, small, or both, and the field's capital, regulatory momentum, and likely first approval all sit in the United States. That's the sober half.

The other half: in six months, an EU member state legalised psychedelic prescribing, the EMA put a psychedelic on its priority track, two European-origin companies locked Phase 3 programmes in the same lane, and Europe's access routes started producing publishable evidence. The field's centre of gravity is American. Its second pole is forming here, slowly, legally, and country by country. This newsletter exists to track exactly that.

If something here is wrong, please tell me, and I will correct it openly.

Thank you so much for reading

Dhruv

Sources